Journal of the European Academy of Dermatology and Venereology : JEADVLetter
20
Feb
2025
Two cases of cerebrovascular accidents following the induction dose of risankizumab.
No abstract available
References:
Poizeau F, Ait‐Oufella H, Bachelez H. Biologics targeting interleukin (IL)‐23 and the risk of cardiovascular events: where are we? J Eur Acad Dermatol Venereol. 2025. https://doi.org/10.1111/jdv.20128
Woods RH. Potential cerebrovascular accident signal for risankizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS). Br J Clin Pharmacol. 2023;89(8):2386–2395.
Shu Y, Chen J, Ding Y, Zhang Q. Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system. Front Immunol. 2023;14:1169735.
Calapai F, Ammendolia I, Cardia L, Currò M, Calapai G, Esposito E, et al. Pharmacovigilance of Risankizumab in the treatment of psoriasis and arthritic psoriasis: real‐world data from EudraVigilance database. Pharmaceutics. 2023;15(7):1933.
Sinvhal R, Krueger WS, Kilpatrick RD, Coppola D. Letter to the editor Concerning the article: ‘Potential cerebrovascular accident signal for risankizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS)’. Br J Clin Pharmacol. 2023;89(8):2639–2641.